Bulletin TREND | COVID-19 n°2
Drug use, drug supply and professional practices in France at the time of COVID-19: qualitative cross-observations of the TREND scheme
Memo, OFDT, 6 p.
N° 2 - April-May 2020
The development of the COVID-19 epidemic and the implementation of lockdown measures by the French public authorities in mid-March 2020 changed the consumption practices of drug users and disrupted the activities of trafficking networks.
In order to better understand these developments, the French Monitoring Centre for Drugs and Drug Addiction (OFDT) has appealed to the eight local centres in its Emerging Trends and New Drugs (TREND) monitoring system (Bordeaux, Lille, Lyon, Marseille, Metz, Paris, Rennes, Toulouse).
After an initial bulletin covering the first three weeks of lockdown (from mid-March to the first week of April 2020), this updated overview includes the data collected between 7 April and 7 May in order to document in greater detail the following three themes:
- the adaptation strategies adopted by users (abstinence and forced or consensual withdrawal, overconsumption, compensation and transfers to other products, etc.);
- the ways in which health care and risk reduction facilities have changed their practices and activities in order to best pursue their missions;
- and the transformations concerning trafficking networks.
Author : Clément Gérome, Michel Gandilhon
Download the PDF file (679 Ko)
Drugs in Europe
What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2019 EMCDDA European Drug Report.
Country drug reports 2019
Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.